PMID- 37511569
OWN - NLM
STAT- MEDLINE
DCOM- 20230803
LR  - 20230803
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 14
DP  - 2023 Jul 22
TI  - mTOR Signaling Pathway and Gut Microbiota in Various Disorders: Mechanisms and 
      Potential Drugs in Pharmacotherapy.
LID - 10.3390/ijms241411811 [doi]
LID - 11811
AB  - The mammalian or mechanistic target of rapamycin (mTOR) integrates multiple 
      intracellular and extracellular upstream signals involved in the regulation of 
      anabolic and catabolic processes in cells and plays a key regulatory role in cell 
      growth and metabolism. The activation of the mTOR signaling pathway has been 
      reported to be associated with a wide range of human diseases. A growing number 
      of in vivo and in vitro studies have demonstrated that gut microbes and their 
      complex metabolites can regulate host metabolic and immune responses through the 
      mTOR pathway and result in disorders of host physiological functions. In this 
      review, we summarize the regulatory mechanisms of gut microbes and mTOR in 
      different diseases and discuss the crosstalk between gut microbes and their 
      metabolites and mTOR in disorders in the gastrointestinal tract, liver, heart, 
      and other organs. We also discuss the promising application of multiple potential 
      drugs that can adjust the gut microbiota and mTOR signaling pathways. Despite the 
      limited findings between gut microbes and mTOR, elucidating their relationship 
      may provide new clues for the prevention and treatment of various diseases.
FAU - Gao, Yuan
AU  - Gao Y
AD  - College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing 
      100044, China.
FAU - Tian, Tian
AU  - Tian T
AUID- ORCID: 0000-0002-5815-282X
AD  - College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing 
      100044, China.
LA  - eng
GR  - 5222019/Natural Science Foundation of Beijing/
PT  - Journal Article
PT  - Review
DEP - 20230722
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - W36ZG6FT64 (Sirolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Gastrointestinal Microbiome/physiology
MH  - Gastrointestinal Tract/metabolism
MH  - Mammals/metabolism
MH  - Signal Transduction/physiology
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/metabolism
PMC - PMC10380532
OTO - NOTNLM
OT  - gut microbes
OT  - mTOR
OT  - metabolites
OT  - therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:49
MHDA- 2023/07/31 06:43
PMCR- 2023/07/22
CRDT- 2023/07/29 01:25
PHST- 2023/06/12 00:00 [received]
PHST- 2023/07/15 00:00 [revised]
PHST- 2023/07/18 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/29 11:49 [pubmed]
PHST- 2023/07/29 01:25 [entrez]
PHST- 2023/07/22 00:00 [pmc-release]
AID - ijms241411811 [pii]
AID - ijms-24-11811 [pii]
AID - 10.3390/ijms241411811 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jul 22;24(14):11811. doi: 10.3390/ijms241411811.